

SESSIONS

PRE EVENTS FRIDAY 2 NOVEMBER - SUNDAY 4 NOVEMBER - 04/11/2018

BIO-Europe

November 5–7, 2018
Bella Center Copenhagen
Copenhagen, Denmark

Advanced Business Development Course

07:30 - 17:00

NOVEMBER 2–4, 2018 // BIO-EUROPE PRE-EVENT //
ADDITIONAL REGISTRATION FEE

The Advanced Business Development Course is an intensive three-day workshop for professionals in the pharmaceutical industry who want to bring their skills in valuation, deal structuring, due diligence, negotiation and contracts to the next level.

For more information [click here](#)

(SOLD OUT) Just arrived in Copenhagen? On these two classical tours professional guides will give you a great introduction to the wonderful City of Copenhagen!

13:00 - 18:30

NOVEMBER 4, 2018 // Copenhagen Sight-Seeing Tour exclusive to BIO-Europe attendees, choice of two //Additional fee

PRESENTATION

SOCIAL PROGRAM FOR BIO-EUROPE ATTENDEES (SOLD OUT)

Tour 1, 15:30–18:30:

Copenhagen Highlights with a visit to Carlsberg Listen to the riveting stories of the must-see highlights like The Royal Palace Amalienborg, Christiansborg and New Harbour with the colorful houses. Explore some of the old parts of Copenhagen and find out why this city is one of the coolest and liveable in Northern Europe. Get some fun facts and anecdotes of green everyday life with sustainable initiatives and bike cycle culture. You will also visit the brewery of Carlsberg, the third largest brewery in the world.

Tour 2, 13:00–16:00:

Copenhagen Highlights with a HYGGE twist Listen to the riveting stories of the must-see highlight like The Royal Palace Amalienborg, Castle Island and New Harbour. How does a constitutional monarchy work? Why is the queen so popular? Become familiar with our Royal Family as you listen to passionate love stories and royal scandals from back in time.

Early Registration

14:00 - 19:00

Main Agenda

Bella Center Copenhagen, Copenhagen, Denmark

REBBLsXLabiotech Science PubCrawl

15:00 - 18:30

NOVEMBER 4, 2018 // REBBLsXLabiotech Science PubCrawl

Beer and science are inadvertently connected here in Copenhagen. You'll oftentimes see that science drives the development of great beers and simultaneously, a couple of beer lead to great science! To celebrate this synergy, REBBLs together with Labiotech, is hosting a pub crawl with a scientific twist to all people who are visiting BIO-Europe.

REBBLs will take you past five of the absolute best pubs in downtown Copenhagen while we highlight some of the many scientific curiosities. It will be a great opportunity for BIO-Europe visitors to network and learn, not only about Copenhagen, but also about famous Danish scientists who have walked the very same streets and had some of the fantastic beers that are brewed here in the Nordics.

We'll have people joining from academia, pharma, biotech and venture capital.. This informal event is nice start to your BIO-Europe and one can subsequently attend the official opening reception.

Only 40 spots - [Please register](#)

About REBBLs

REBBLs creates real connections between ambitious professionals who are in the Danish life science innovation space. We challenge the convention and inspire entrepreneurial mindsets by facilitating rebellious events. We do this by organizing a wide variety of events such as our trademark 'Beers with Peers', workshops, ideations and much more. In addition, REBBLs organizes pitch training sessions to bring out the best of startups aiming for the top. Lastly, REBBLs make networking fun and meaningful. We aim to broaden your personal and business network. See also [rebbles.dk](#) for more information.

About Labiotech.eu

Labiotech.eu is the leading digital media covering the European Biotech industry. Over 100,000 monthly visitors use it to keep an eye on the business and innovations in biotechnology. "We are building the Next Generation of Digital Media for Biotech"

Welcome Reception, Sunday 4 November

19:00 - 21:00

Main Agenda

Venue address: Copenhagen City Hall | Rådhuspladsen 1 | 1599 København V

Copenhagen City Hall is the headquarters of the municipal council as well as the Lord Mayor of the Copenhagen Municipality, Denmark. The building is on The City Hall and was built in 1892–1905. It was designed by the architect Martin Nyrop in the National Romantic style, drawing inspiration from the Siena City Hall, Italy. In recent years The City Hall has been used for scenes in Danish hit TV series like "The Killing" and "Borgen."

All BIO-Europe attendees are cordially invited to join us for the welcome reception. You will be able to pick up your name badge at the welcome reception between 19:00–21:00.

Sunday, November 4, 2018, 19:00–21:00

[View website](#)

SCHEDULE

PRE EVENTS FRIDAY 2 NOVEMBER - SUNDAY 4 NOVEMBER - 04/11/2018

BIO-Europe

November 5–7, 2018
Bella Center Copenhagen
Copenhagen, Denmark

TIME	MAIN AGENDA	NOVEMBER 2–4, 2018 // BIO-EUROPE PRE-EVENT // ADDITIONAL REGISTRATION FEE	NOVEMBER 4, 2018 // COPENHAGEN SIGHT-SEEING TOUR EXCLUSIVE TO BIO-EUROPE ATTENDEES, CHOICE OF TWO // ADDITIONAL FEE	NOVEMBER 4, 2018 // REBBLSLABIOTECH SCIENCE PUBCRAWL
07:00		07:30 - Advanced Business Development Course		
08:00				
09:00				
10:00				
11:00				
12:00				
13:00			13:00 - (SOLD OUT) Just arrived in Copenhagen? On these two classical tours professional guides will give you a great introduction to the wonderful City of Copenhagen!	
14:00	14:00 - Early Registration			
15:00				15:00 - REBBLsXLabiotech Science PubCrawl
16:00				
17:00				
18:00				

SCHEDULE

PRE EVENTS FRIDAY 2 NOVEMBER - SUNDAY 4 NOVEMBER - 04/11/2018

BIO-Europe

November 5–7, 2018
Bella Center Copenhagen
Copenhagen, Denmark

TIME	MAIN AGENDA	NOVEMBER 2–4, 2018 // BIO-EUROPE PRE-EVENT // ADDITIONAL REGISTRATION FEE	NOVEMBER 4, 2018 // COPENHAGEN SIGHT-SEEING TOUR EXCLUSIVE TO BIO-EUROPE ATTENDEES, CHOICE OF TWO //ADDITIONAL FEE	NOVEMBER 4, 2018 // REBBLSLABIOTECH SCIENCE PUBCRAWL
19:00	19:00 - Welcome Reception, Sunday 4 November			

SESSIONS

DAY 1 - 05/11/2018

BIO-Europe

November 5–7, 2018
Bella Center Copenhagen
Copenhagen, Denmark

Registration and Exhibition Open

07:45 - 18:00
Main Agenda

Registration: Entrance

Exhibition: Hall E and Hall C

Continental Breakfast

07:45 - 09:00
Networking

Hall E

Pediatrics: Searching new drug solutions for the people we love most

09:00 - 10:30
Workshop 1

Room B1

Children and adolescents show quite significant physiological differences that are relevant for drug development in that target patient group. These include for instance different pharmacokinetics, bioavailability of drug substance and renal clearance, risk of overdosing, increased sensibility of the growing organism.

The available database of approved drugs in adults is therefore quite insufficient and many drugs that are used in children today are not formally approved in children by the regulatory bodies.

We believe that pediatrics provides an exciting area for biotechnology companies in the future.

Our panel will explore the challenges and opportunities for drug development, clinical studies and new formulations for children including a review of the regulatory context both in the US and Europe.

Participants

Moderator: Hubert Birner - Managing Partner, TVM Life Science Management Inc.

Panelist: Andréa Gilpin - General Manager, The Goodman Family Pediatric Formulations Centre, Montreal, Canada

Panelist: Michael Mehler - CEO, leon-nanodrugs GmbH

Panelist: Arndt Rolfs - CEO, Centogene

Panelist: Robert Schott - Chief Medical Officer, Chorus Division, Eli Lilly and Company

The path to market: To go it alone or to seek a partner

09:00 - 10:30
Workshop 2

Room B2

Innovator companies, founded around novel technology platforms or new therapeutic assets, have an increasingly diverse option set available to them as they look to advance their programs through clinical development to regulatory approval and, ultimately, to commercial launch. The financial options to fuel this progress range throughout the journey—from early angel and venture funding to established pharma and biotech partnerships to equity offerings to non-dilutive funding mechanisms to outlicensing. All come with a different set of implications, from capability access through to balance sheet health, that affect the probability of a successful journey as well as the value that the company can create through that journey. Join us for an executive conversation where we hear from innovators, preferred partners, and others involved in the funding process about how these decisions are approached and when companies may best look to collaborate.

Participants

Moderator: Sam Ulin - Principal, ClearView Healthcare Partners

Panelist: Debbie Allen - Senior VP Business Development, Argenx

Panelist: Berthold Hinzen - Head of BD&L Therapeutic Areas, Bayer AG

Panelist: Peter Ho - Senior Director Business Development, BeiGene Switzerland GmbH

EBD Academy Buzz Session: Selecting the right partner

09:00 - 09:30
EBD Academy Buzz Session

Room B4

Identifying the right partner for your asset(s) and company is essential for partnering success, but what are the key factors you should look for when deciding who to approach and commit to? This session will help you define what criteria you should be using, how to develop a base of potential partners and finally how to screen for the best possible match. You will benefit from the workshop leader's 25+ years' experience in the business development space and will have the chance to share your own thoughts.

What we will cover:

- Scientific fit – therapeutic areas, resources, technology platforms etc
- Business fit – strategic and cultural alignment, other products in the target's portfolio
- Discussions to select your partners- capabilities, development plan, scope, deal structure, your ongoing role
- Managing the process
- What can you learn during the negotiation process?

Participants

Speaker: Linda Pullan - President, Pullan Consulting

One-to-one meetings

10:00 - 18:00
Partnering

Hall C

10:00 – 18:30 Please note: One-to-one meetings will take place all day depending on your partnering schedule.

Welcome and Opening Remarks

10:45 - 11:15
Plenary

Room C1

Participants

Speaker: Anna Chrisman - Managing Director, EBD Group and Knect365 Life Sciences

Speaker: Claus Lønborg - CEO, Copenhagen Capacity

Speaker: Stefan Johansson - CEO, Invest in Skåne

Speaker: David Thomas - VP, Industry Research, Biotechnology Innovation Organization (BIO)

SESSIONS

DAY 1 - 05/11/2018

BIO-Europe

November 5–7, 2018
Bella Center Copenhagen
Copenhagen, Denmark

Opening Plenary Discussion: Europe: The global innovation trailblazer

11:15 - 12:30
Plenary

Room C1

This year's opening plenary will discuss Europe's key position in the global innovation ecosystem and explore strategies to ensure that European research will be successful in an international marketplace. As growth often depends on collaborations across borders, the panel will examine success stories from Europe, and highlight strategies to help invigorate entrepreneurs by nurturing partnerships, share best practices from external resources, and intelligently secure funding in order to expand research within Europe and beyond.

Participants

Co-moderator: Mette Kirstine Agger - Managing Partner, Lundbeckfonden Ventures

Co-moderator: Thomas Dyrberg - Managing Partner, Novo Ventures

Panelist: Sir Harpal Kumar - Head, Johnson & Johnson Innovation, EMEA

Panelist: Werner Lanthaler - CEO, Evotec

Panelist: Marcus Schindler - Senior VP, Global Drug Discovery, Novo Nordisk R&D

Panelist: Onno van de Stolpe - CEO, Galapagos

Luncheon

12:00 - 14:00
Networking

Seated Luncheon Hall B

Grab & Go Lunch Hall E

Partnering trends in the pharma world: How does big pharma expand pipeline opportunities?

13:30 - 14:30
Business Development

Room B3–B4

Participants

Moderator: Isabelle Marguet - National Partner, Dechert

Panelist: Pierre Courteille - Chief Commercial Officer, VP Business Development, Abivax

Panelist: Lubor Gaal - Senior VP, Head of Europe, Locust Walk

Panelist: Rahul Jerath - Senior Director, Business Development and Acquisitions, AbbVie

Panelist: Barbara Sosnowski - VP, External Science & Innovation, Pfizer

Microbiome and the implication on other therapeutic areas

13:30 - 14:30
Therapeutic

Room C2

Participants

Moderator: Eric de La Fortelle - Managing Director, Health Opportunities GmbH

Panelist: Isabelle de Cremoux - CEO, Seventure

Panelist: Per Falk - Executive VP and CSO, Ferring Pharmaceuticals

Panelist: Mohamad Mohty - Professor of Hematology, Sorbonne University, Saint-Antoine Hospital, Paris, France

Panelist: Mike Romanos - CEO, Microbiotica

Panelist: David Braga Malta - Founder & CEO, Neurimm Therapeutics

AI's implications for the future of drug discovery

13:30 - 14:30
Spotlight on Digital Health

Room B1–B2

While machine learning and artificial intelligence (AI) have had a deep impact in solving complex global problems over the past several years, there has been a slow adoption and implementation of these technologies for use in drug discovery R&D. AI-based technologies and platforms in the life sciences are still in their infancy, but this will be the way of the future for generating drugs and diagnostics. In this panel discussion, we bring together thought-leaders in machine learning and artificial intelligence to delve into the opportunities, capabilities, future trends and challenges of using AI to speed up drug discovery, decrease failure rates in drug trials and create more affordable and better treatments for patients.

Participants

Moderator: Dave Madge - VP, Research Service Division, WuXi AppTec

Panelist: Daniel Crowther - Chief Bioinformatician, Exscientia Ltd

Panelist: Martin Gouldstone - Chief Business Office, BenevolentAI

Panelist: Peter Hamley - External Innovation Head, Drug Discovery Platform, Sanofi

Panelist: Noor Shaker - CEO, GTN Ltd.

Pharma Company Presentations

14:00 - 17:30
Presentations

Room C1

14:00 Amgen

Presenter: Olaf Koenig - Director, Business Development

14:15 Sanofi

Presenter: Olivier Reinhard - Head of General Medicines & Emerging Markets, Global Business Development and Licensing

14:30 Johnson & Johnson Innovation

Presenter: Tahera Kan - Senior Director, Global Business Development, Divestitures Johnson & Johnson Innovation, Janssen Business Development

14:45 Bristol-Myers Squibb

Presenter: Matthew Roden - Head of Strategic Corporate Development and Global Business Development Assessment

15:00 MSD

Presenter: Phil L'Huillier - Head, European Innovation Hub Business Development & Licensing

15:15 Roche/Genentech

Presenter: James Sabry - Global Head Pharma Partnering

15:30 AbbVie

Presenter: Rahul Jerath - Senior Director, Business Development

15:45 Merck

Presenter: Brendan Luu - VP, Head of Oncology BD

16:00 Boehringer Ingelheim

Presenter: Bernd Nosse - Global Head of BD&L Technologies

16:15 Bayer

Presenter: Christoph Geserick, Senior Director

SESSIONS

DAY 1 - 05/11/2018

BIO-Europe

November 5–7, 2018
Bella Center Copenhagen
Copenhagen, Denmark

16:30 Novo Nordisk

Presenter: Florence Dal Degan - Director, Search & Evaluation, Global Drug Discovery

16:45 Servier

Presenter: Didier Landais - Global Head of Licensing

17:00 Novartis Pharma

Presenter: Patrick Mueller - World Wide Head Search & Evaluation, Business Development & Licensing

17:15 Eli Lilly and Company

Presenter: Heather Wasserman - Vice President, Emerging Technology & Innovation – Global

Partnering opportunities with Chinese investors

14:45 - 15:45
Business Development

Room B3–B4

The number of M&A transactions involving Chinese investors and targets in Europe continuously increases. Chinese foreign direct investments in Europe hit a record EUR 65 billion in 2017, compared with less than EUR 2 billion in 2010. Evidently, Europe has become progressively more attractive for Chinese investors.

While it is not uncommon for transnational transactions between European targets and Chinese investors to fail due to cultural and communicative differences, significant progress has been made to help ensure greater successful transactions. Beyond the intrinsic challenges with R&D, legal hurdles have to be overcome and other critical factors must be taken into account in order to have successful cross-border collaborations. This panel will discuss the experiences and necessary considerations of intercultural dealings with investors as well as provide practical solutions.

Participants

Moderator: Peter Homberg - Partner, Dentons

Panelist: Katherine Cohen - Venture Partner, Panacea Venture

Panelist: Ji Li - Venture Partner, Lilly Asia Ventures

Panelist: Greg Scott - Founder and Chairman, ChinaBio® Group

Panelist: Dan Zhang - CEO, Fountain Medical Development Ltd.

Trends in rare disease investment, research and orphan drug development

14:45 - 15:45
Therapeutic

Room C2

Rare diseases are increasingly prevalent and a key part of many companies' strategies, suggesting that rare diseases, and the orphan drugs that treat them, can be a lucrative investment. It's not surprising with the proliferation of orphan drug programs, and their associated regulatory and commercial incentives, but are there other factors and are they more successful overall?

Participants

Moderator: Jamie Munro - Global Practice Leader, Portfolio & Licensing, Clarivate Analytics

Panelist: Charles Bailey - Neuroscience BD&L, Novartis Pharma AG

Panelist: Michelle Chen - Senior Director Corporate and Business Development, BioMarin Pharmaceutical Inc.

Panelist: Tom Kassberg - Chief Business Officer and Executive VP, Ultragenyx Pharmaceuticals

Panelist: Raphaël Wisniewski - Partner, Andera Partners

Digital therapeutics: New "smart" treatments have the potential to alter the landscape of our industry

14:45 - 15:45
Spotlight on Digital Health

Room B1–B2

New "smart" treatments have the potential to alter the landscape of our industry. How are these products different from traditional biopharma products? What are the development, regulatory and reimbursement pathways? What are the challenges to adoption of these new tools and how can we maximize the opportunities to provide alternatives to traditional medications? Companies paving the path in this exciting new sector will discuss this next wave of innovation in the life sciences.

Participants

Moderator: Natalie Dakers - President and CEO, Accel-Rx Health Sciences Accelerator

Panelist: Antoun Nabhan - VP, Corporate Development, Pear Therapeutics, Inc.

Panelist: Austin Speier - Chief Strategy Officer, Click Therapeutics

Panelist: John Zibert - Chief Medical Officer, LEO Innovation Lab

How pharma and VC collaborations are changing the industry

16:00 - 17:00
Business Development

Room B3–B4

In recent years, pharma company R&D budgets have been under pressure. Pharma companies are struggling to find ways to continue to advance the development of attractive drug candidates from their own pipelines while simultaneously looking outside for attractive programs they can acquire. One way pharma companies can do more within a constrained R&D budget is to partner with outside investors in innovative ways in order to develop attractive drug candidates with "other people's money." This panel of industry experts will explore some of the ways that pharma companies and VC firms are partnering to develop drugs and generate investment returns.

Participants

Moderator: Neel Patel - Managing Director, Syneos Health Consulting

Panelist: James Cornwall - Chief Business Officer, Nuvelution Pharma, Inc.

Panelist: Reza Halse - President, MRL Venture Fund, MSD

Panelist: Genghis Lloyd-Harris - Partner, Abingworth

Panelist: Ruth McKernan - Consultant, Dementia Discovery Fund Team, SV Health Managers LLP

Panelist: Matt Roden - VP, Global Business Development Assessment and Strategic Corporate Development, Bristol-Myers Squibb

SESSIONS

DAY 1 - 05/11/2018

BIO-Europe

November 5–7, 2018
Bella Center Copenhagen
Copenhagen, Denmark

Business development strategies in I-O: Compete – Combine – Collaborate

16:00 - 17:00
Therapeutic

Room C2

Immuno-oncology has transformed the oncology sector via offering new and highly effective treatments for an increasing number of cancers, rapidly evolving science and an unprecedented number of assets in preclinical and clinical development. The promise of cancer immunotherapy has fueled an intense global race not only for being first-in-class or best-in-class with one treatment modality but also for identifying potential first-in-class combinations and rapidly advancing them in partnerships and combination deals.

The panel gathers experienced experts from the public, biotech and pharma sector to discuss the associated business development challenges and opportunities as well as adoptive strategies needed to succeed in a quickly evolving and increasingly crowded field.

Participants

Moderator: Jutta Heix - International Advisor, Oslo Cancer Cluster

Panelist: Khatereh Ahmadi - Executive Director, Business Development and Licensing, MSD

Panelist: Jette Asboe Lassen - VP, Business Development, Symphogen

Panelist: Bernd Mühlenweg - Chief Business Officer, Nanobiotix

Panelist: Per Norlen - CEO, Alligator Bioscience

Panelist: Michael Salgaller - Invention Development and Marketing Unit (IDMU), Technology Transfer Center, National Cancer Institute, National Institutes of Health

BREAK AND BREATHE

16:05 - 16:25
Extra Activity

Upper Level, Room 17

Enhance your conference experience by using simple breathing techniques, movement and light stretches in order to charge your body and mind for better decision making and more energy throughout the day.

Open to all. No prerequisites required. Standing and seated positions only.

BREAK AND BREATHE

16:35 - 16:55
Extra Activity

Upper Level, Room 17

Enhance your conference experience by using simple breathing techniques, movement and light stretches in order to charge your body and mind for better decision making and more energy throughout the day.

Open to all. No prerequisites required. Standing and seated positions only.

How are geopolitics affecting biopharma's future prospects?

17:15 - 18:15
Business Development

Room B3–B4

Two years ago, BIO-Europe delegates woke up on the third day of the meeting with the news that Donald Trump had beaten Hillary Clinton in the race to the White House. That result came in just four and a half months after the British people had voted narrowly to leave the European Union. Both results were a shock to both the political establishment and pharma executives that abhor any kind of uncertainty. Two years on, how has pharma adapted to the new geopolitical landscape? What challenges lie ahead and what should pharma do to manage any risks involved?

Participants

Moderator: Mike Ward - Head of Content, Informa Pharma Intelligence Insights

Panelist: David Colpman - Director,, Colpman Consulting Ltd

Panelist: Joe Damond - Executive VP, International Affairs, Biotechnology Innovation Organization (BIO)

Panelist: Jonas Ekstrand - Director General, SwedenBIO

Panelist: Barbara Freischem - Executive Director, European Biopharmaceutical Enterprises

The current climate of CNS R&D: Lessons learned and new research

17:15 - 18:15
Therapeutic

Room C2

This panel will cover the current climate of CNS R&D, specifically lessons learned from past failures and new research to advance the treatment of neurological disorders. CNS disorders are expected to make up 14.7 percent of the global disease burden by 2020, representing the largest burden of any disease group, according to the US National Institute of Mental Health. Despite decades of research and billions in investments, this sector has posed significant challenges and setbacks. However, ambitious novel research and new breakthroughs are changing the landscape. Experts in this field will highlight what is being done differently now and discuss the future of CNS in biopharma.

Participants

Moderator: Olga Uspenskaya-Cadoz - Senior Medical Director, Central Nervous System Center of Excellence, Medical Strategy & Science, Therapeutic Science & Strategy Unit, IQVIA

Panelist: Dirk Behr - CEO and Founder, Asceneuron SA

Panelist: Martin Citron - VP Neuroscience, UCB

Panelist: Deborah Dunsire - President and CEO, Lundbeck

Panelist: Alexis Genin - Head of Research & Technology Development, ICM

Panelist: Spiros Liras - VP External Portfolio Innovation Unit, Biogen

Champagne reception at EBD Group booth

17:45 - 18:45
Networking

There are two locations for the reception.

Hall C, Exhibit, Lounge
Time: 18:00 – 18:45

AND

Hall E, Exhibit

SESSIONS

DAY 1 - 05/11/2018

BIO-Europe

November 5–7, 2018
Bella Center Copenhagen
Copenhagen, Denmark

Evening Networking Reception

19:00 - 22:00
Networking

Venue address:

The Royal Danish Opera House | Ekvipagemestervej 10
| 1438 København K

The landmark architecture of The Opera House offers the perfect setting, with its transparent grand foyer, panoramic views, sculpted maple wood interiors and artist Olafur Eliasson's magnificent light sculptures. It is a donation from the A.P. Møller and Chastine McKinney Møller Foundation to the Danish people. The Opera House is clad with southern German Jura Gelb limestone, and the foyer features Sicilian Perlatino marble. The wall of the auditorium facing the foyer is clad with maple wood, and the ceiling in the main auditorium is adorned with 105,000 sheets of 24 carat gold leaf, equivalent to 1.5 kilos of gold.

Monday, November 5, 2018, 19:00–22:00

[View website](#)

Buses:

18:30–19:15 Shuttle buses depart from the conference center to the evening event.

21:00–22:00 Shuttle buses depart from the evening event to all conference hotels.

SCHEDULE

DAY 1 - 05/11/2018

BIO-Europe

November 5–7, 2018
Bella Center Copenhagen
Copenhagen, Denmark

TIME	BUSINESS DEVELOPMENT	EBD ACADEMY BUZZ SESSION	EXTRA ACTIVITY	MAIN AGENCY	NETWORKING	PARTNERING	PLENARY	PRESENTATIONS	SPOTLIGHT ON DIGITAL HEALTH	THERAPEUTIC	WORKSHOP 1	WORKSHOP 2
07:00				07:45 - Registration and Exhibition Open	07:45 - Continental Breakfast							
08:00												
09:00		09:00 - EBD Academy Buzz Session: Selecting the right partner									09:00 - Pediatrics: Searching new drug solutions for the people we love most	09:00 - The path to market: To go it alone or to seek a partner
10:00						10:00 - One-to-one meetings	10:45 - Welcome and Opening Remarks					
11:00							11:15 - Opening Plenary Discussion: Europe: The global innovation trailblazer					
12:00					12:00 - Luncheon							

SCHEDULE

DAY 1 - 05/11/2018

BIO-Europe

November 5–7, 2018
Bella Center Copenhagen
Copenhagen, Denmark

TIME	BUSINESS DEVELOPMENT	EBD ACADEMY BUZZ SESSION	EXTRA ACTIVITY	MAIN AGENDA	NETWORKING	PARTNERING	PLENARY	PRESENTATIONS	SPOTLIGHT ON DIGITAL HEALTH	THERAPEUTIC	WORKSHOP 1	WORKSHOP 2
13:00	13:30 - Partnering trends in the pharma world: How does big pharma expand pipeline opportunities?								13:30 - AI's implications for the future of drug discovery	13:30 - Microbiome and the implication on other therapeutic areas		
14:00	14:45 - Partnering opportunities with Chinese investors							14:00 - Pharma Company Presentations	14:45 - Digital therapeutics: New "smart" treatments have the potential to alter the landscape of our industry	14:45 - Trends in rare disease investment, research and orphan drug development		
15:00												
16:00	16:00 - How pharma and VC collaborations are changing the industry		16:05 - BREAK AND BREATHE 16:35 - BREAK AND BREATHE							16:00 - Business development strategies in I-O: Compete – Combine – Collaborate		

SCHEDULE

DAY 1 - 05/11/2018

BIO-Europe

November 5–7, 2018
Bella Center Copenhagen
Copenhagen, Denmark

TIME	BUSINESS DEVELOPMENT	EBD ACADEMY BUZZ SESSION	EXTRA ACTIVITY	MAIN AGENCY	NETWORKING	PARTNERING	PLENARY	PRESENTATIONS	SPOTLIGHT ON DIGITAL HEALTH	THERAPEUTIC	WORKSHOP 1	WORKSHOP 2
17:00	17:15 - How are geopolitics affecting biopharma's future prospects?				17:45 - Champagne reception at EBD Group booth					17:15 - The current climate of CNS R&D: Lessons learned and new research		
18:00												
19:00					19:00 - Evening Networking Reception							

SESSIONS

DAY 2 - 06/11/2018

BIO-Europe

November 5–7, 2018
Bella Center Copenhagen
Copenhagen, Denmark

Rise and Run for children with cancer

06:30 - 07:30
Extra Activity

Meeting at: Radisson Blu, Amager Blvd 70, 2300 Copenhagen

Ease yourself into a busy second day at BIO-Europe with a morning run. Led by a Copenhagen trainer, you will enjoy light sightseeing through the streets of Copenhagen. The pace will be comfortable enough to chat and runners of all levels are welcome.

Improve Cancer Care for some of the world's poorest children. Runners and non-runners may donate at: <https://www.justgiving.com/fundraising/riseandrun>.

Registration and Exhibition Open

07:45 - 18:00
Main Agenda

Registration: Entrance

Exhibition: Hall E and Hall C

Continental Breakfast

07:45 - 09:00
Networking

Hall E

One-to-one meetings

08:00 - 18:30
Partnering

Hall C

10:00 –18:30 Please note: One-to-one meetings will take place all day depending on your partnering sch

Commercialization of cell and gene therapies

09:00 - 10:00
Cell and Gene

Room B4

As the science continues to advance in this sector, the commercialization models need to catch up to meet the complex demands of these unique therapies. In order to accelerate the commercialization of these products, the manufacturing process needs to be scalable, affordable, and efficient. Patient safety comes first, and companies are seeking opportunities to improve safety and extend survival. These goals must be executed simultaneously which is easier said than done. Hear experts discuss the infrastructure needed to develop best practices for manufacturing and providing the safe and effective delivery of cell and gene therapies.

Participants

Moderator: Sarah Rickwood - VP, European Thought Leadership, IQVIA

Panelist: Henrik Luessen - Chief Business Officer, Promethera

Panelist: Jason Meyenburg - Chief Commercial Officer, Orchard Therapeutics

Panelist: Jason Slingsby - Head, Business Development, Oxford BioMedica

University of Copenhagen – Building value out of curiosity: How basic research leverages the biopharmaceutical industry

09:00 - 10:30
Academic Presentations

Room B3

MODERATOR:

Trine Winterø – Vice-Dean for Innovation and External Relations, Faculty of Health and Medicine, Copenhagen University

PRESENTERS:

Zachary Gerhart-Hines – Associate Professor, NNF Center for Basic Metabolic Research

Developing novel calorie-burning strategies to combat obesity and metabolic disease

Janine Erler – Professor, BRIC, University of Copenhagen

New approaches to targeting cancer

Kristian Strømgaard – Professor and Director, Center for Biopharmaceuticals, Department of Drug Design and Pharmacology

AVLX-144 as a novel treatment for stroke

Jacqueline Ameri – Assistant Professor, CEO & Founder of PanCryos, Novo Nordisk Foundation Center for Stem Cell Biology, DanStem

PanCryos – Developing a best in class cell therapy for treatment of insulin dependent diabetes

Lone Skov – Professor, Managing Director, Department of Skin and Allergy, Herlev and Gentofte Hospital, Department of Clinical Medicine, University of Copenhagen

Drug development for the skin is privileged

SESSIONS

DAY 2 - 06/11/2018

BIO-Europe

November 5–7, 2018
Bella Center Copenhagen
Copenhagen, Denmark

EU research funding for SMEs

09:00 - 10:30
Additional Program

Room B5

How can innovative and ambitious small and medium-sized enterprises (SMEs) in the health and related sectors access European Union (EU) funds for research and innovation? What do different programs offer SMEs, and what are the benefits of participation in addition to funding?

This session will showcase the latest opportunities under Horizon 2020, including the dedicated SME program and the collaborative research schemes, as well as the Innovative Medicines Initiative, a public-private partnership between the EU and the European pharmaceutical industry that has helped many SMEs to advance their research and grow their business. It will also spotlight European Investment Bank programs of relevance to SMEs. Finally, a representative of an SME who has experience participating in EU research and innovation projects will tell their story and offer firsthand advice for SMEs considering applying for funding. Looking to the future, the session will also include an overview of the European Commission's plans for Horizon Europe, the framework program for research and innovation for 2021 to 2027.

Participants

Moderator: Pierre Meulien - Executive Director, Innovative Medicines Initiative

Panelist: Laszlo Helmle - Policy Officer, Health Directorate, European Commission

Panelist: Auvo Kaikkonen - Senior Life Science Specialist, European Investment Bank (EIB)

Panelist: Morten Karsdal - CEO, Nordic Bioscience

Panelist: Nick Lynch - CTO, Open PHACTS Foundation

Power up partneringONE: Essentials

09:00 - 09:30
Workshops

Hall C, Room 393

This session is for delegates new to partnering. What you can expect out of partnering, and what others expect from you will form the basis of this workshop. Principles around timing, human nature, and partnering etiquette will be applied to the partneringONE process. Come away from the session with a clear understanding of what you can do to generate the best ROI from partnering, at this and future events.

This session is being offered multiple times during BIO-Europe. Each session is limited to 9 people. Please reserve your seat by adding the session to your personal agenda in your partnering account. Or drop by the Power Zone, by the partnering help desk, with any questions.

Participants

Speaker: Lisa Methley - Senior Director, Online Strategy, EBD Group

Company Presentations

09:00 - 12:00
Presentations

[2018 list of Presenting Companies](#)

Rooms B1, B2, B3

Cell & Gene Company Presentation Track

10:00 - 11:30
Cell and Gene

Room B4

Capricor Therapeutics

Collect Biotherapeutics

MaxCyte, Inc.

Pluristem Therapeutics

Precision BioSciences

Power up partneringONE: Experienced users

10:00 - 10:30
Workshops

Hall C, Room 393

This session is for delegates familiar with partnering who want to up their game. Best practices for collaborating with colleagues, saving time, increasing response rates and acceptance rates will be discussed in terms of partneringONE, including new power features to support optimal partnering etiquette. Come away from the session with a clear understanding of how partneringONE can support your company to maximize ROI from partnering, at this and future events.

This session is being offered multiple times during BIO-Europe. Each session is limited to 9 people. Please reserve your seat by adding the session to your personal agenda in your partnering account. Or drop by the Power Zone, by the partnering help desk, with any questions.

Participants

Speaker: Lisa Methley - Senior Director, Online Strategy, EBD Group

Spotlight on Denmark: The place to conduct clinical trials

10:45 - 11:45
Additional Program

Room B5

- Life science in Denmark at a glance
- The new Danish growth plan for life science
- Governmental investment in life science—initiatives to support the life science in Denmark
- Public private partnership in research—the story of a public-private partnership and regional services within clinical research
- Danish competitiveness on clinical trials—unique framework conditions
- Q&A

Participants

Speaker: Britta Smedegaard Andersen - Project Director, NEXT (National Experimental Therapy Partnership)

Speaker: Rasmus Beedholm-Ebsen - Special Advisor, Life Science, Invest in Denmark

SESSIONS

DAY 2 - 06/11/2018

BIO-Europe

November 5–7, 2018
Bella Center Copenhagen
Copenhagen, Denmark

BREAK AND BREATHE

11:05 - 11:25
Extra Activity

Upper Level, Room 17

Enhance your conference experience by using simple breathing techniques, movement and light stretches in order to charge your body and mind for better decision making and more energy throughout the day.

Open to all. No prerequisites required. Standing and seated positions only.

Partnering landscape in advanced therapies

11:30 - 12:30
Cell and Gene

Room B4

With the growing number of cell and gene therapy companies around the world, how are companies developing their partnering strategies to leverage new technologies? How are companies working together with research institutions, manufacturers, and other stakeholders to advance research in this exciting sector?

Participants

Moderator: Andrew Moore - Chief Operating Officer, ERA Consulting

Panelist: Karin Agerman - Chief Research and Development Officer, CombiGene AB

Panelist: Kathryn McCabe - Director Business Development- Emerging Technology and Innovation, Eli Lilly and Company

Panelist: Bharat Reddy - Associate Director, Business Development, bluebird bio

Panelist: Dan Shelly - Director, Business Development, Albumedix

BREAK AND BREATHE

11:35 - 11:55
Extra Activity

Upper Level, Room 17

Enhance your conference experience by using simple breathing techniques, movement and light stretches in order to charge your body and mind for better decision making and more energy throughout the day.

Open to all. No prerequisites required. Standing and seated positions only.

Luncheon

12:00 - 14:00
Networking

Seated Luncheon Hall B

Grab & Go Lunch Hall E

Keynote Plenary Discussion: A day in the life of experienced dealmakers

12:30 - 13:30
Plenary

Room C2

Participants

Co-moderator: Evonne Sepsis - Founder and Managing Director, ESC Advisors

Co-moderator: Anton Gueth - Managing Director, EVOLUTION Life Science Partners

Panelist: Sascha Bucher - Head of Global Transactions, Roivant

Panelist: Constantine Chinoporos - CBO, Boston Pharmaceuticals

Panelist: Philippe Lopes-Fernandes - Senior Vice President, Global Head of Business Development & Alliance Management, Merck

Panelist: James Sabry - Global Head, Pharma Partnering, Roche

Biotech company creation in the EU: The role of EU-based VCs

14:00 - 15:00
Panels

Room B5

Today, significant EU-based early stage VCs are all trying to do the "right thing" and build real value in the companies they create, to translate exciting new scientific breakthroughs. Surrounding these companies are strong ecosystems and a growing pool of experienced management talent ready to translate European science which is second to none. The diversity of the EU has the advantage that we have VCs with a range of backgrounds and interests all taking different approaches in how to translate the science. In our company creation session, a range of representatives from EU-based VC funds and pharma companies will explore the pros and cons of models and ideologies applied in financing and building companies, and speculate on the future of the EU biotech system.

Participants

Moderator: Stephan Christgau - Senior Partner, Novo Holdings A/S

Moderator: Christian Elling - Managing Partner, Lundbeckfonden Emerge

Panelist: Jeanne Bolger - VP, Venture Investments, Johnson & Johnson Innovation

Panelist: Rémi Droller - Managing Partner, Kurma Partners

Panelist: Kevin Johnson - Partner, Medicxi

Panelist: Dirk Kersten - General Partner, Forbion

Panelist: Alexander Mayweg - Partner, Versant Ventures

Using new business models to forge stronger partnerships in today's biopharmaceutical industry

14:00 - 15:00
Additional Program

Room B4

The biopharmaceutical world continues to evolve and the path to market for a modern medicine remains complex and uncertain. However, opportunities are emerging to ease the burden on biopharma companies including advances in technology and new models of collaboration to bring products to market faster.

Under the growing pressure of regulation and competition, companies seeking a competitive advantage require partners that offer new and agile approaches for development and manufacture. Speed is key, together with a simple but robust and flexible supply chain that can be adapted to changing demands. From R&D to production to scaleup and supply chain, operational efficiencies can make or break a company. In this workshop, we will discuss how partnering and innovative business models can help companies find a competitive advantage and manage the complexity in the development and manufacturing of modern biopharmaceuticals. What is the optimal strategy for different commercialization scenarios? Our panelists will share their perspectives on solutions across the lifecycle of a product.

Participants

Moderator: Boris Mannhardt - CEO, BIOCOM AG

Moderator: Sandra Wirsching - Director Business Development and Managing Editor, BIOCOM AG

Panelist: Shawn Bridy - VP, Business Development, Inovio Pharmaceuticals

Panelist: Nouhad Hussein - VP, Head of Business Development, Regeneron Pharmaceuticals, Inc.

Panelist: Philippe Lopes-Fernandes - Senior Vice President, Global Head of Business Development & Alliance Management, Merck

Panelist: Jesper Valbjørn - VP, CMC Operations, Genmab A/S

Panelist: Jenifer Wheat - Head of Commercial Development, Mammalian and Microbial Manufacturing, Lonza

Company Presentations

14:00 - 18:00
Presentations

[2018 list of Presenting Companies](#)

Rooms B1, B2, B3

SESSIONS

DAY 2 - 06/11/2018

BIO-Europe

November 5–7, 2018
Bella Center Copenhagen
Copenhagen, Denmark

Startup Slam Copenhagen

15:00 - 18:00
Startup Slam

Room C1

Startup Slam is a pitching competition offering emerging entrepreneurs a chance to pitch their company. Selected companies will present their innovative technologies to a panel of judges comprising business development executives, venture capitalists and industry experts.

For more information please [click here](#)

Participants

Co-moderator: Philip Hemme - Co-Founder and CEO, Labiotech

Co-moderator: Emma Kohring - Innovation Communications Leader, EMEA, Johnson & Johnson Innovation

Judge: Claus Andersson - Partner, Sunstone Life Science Ventures

Judge: Anna Gran - New Ventures Lead, Nordics, Johnson & Johnson Innovation

Judge: Guenter Huhle - Head, JLABS EMEA

Judge: Stefan Luzi - Partner, Gilde Healthcare

Judge: Ingrid Teigland Akay - Managing Partner, Hadean Ventures

Formulation in the drug product development process

15:15 - 16:15
Panels

Room B5

In this roundtable, the panel will examine the key findings of the 2018 Formulation in the Drug Product Development Process survey, conducted by Rentschler Biopharma, Leukocare and Pharma Intelligence. The panel will also share their strategic insights on the importance, expectations, common challenges and future directions of drug product formulation.

Panelists:

- Ann Gidner – Board Member, SenzaGen AB
- Sebastian Meyer – Chief Operating Officer, Numab Innovation AG
- John K. Moore – Director Global Clinical Business Development, Vetter Pharma International USA Inc.
- Federico Pollano – Senior Vice President, Business Development, Rentschler Biopharma SE
- Michael Scholl – Chief Executive Officer, LEUKOCARE AG

Participants

Moderator: Mike Ward - Head of Content, Informa Pharma Intelligence Insights

Make or buy decision and how to select the ideal CDMO

15:15 - 16:15
Additional Program

Room B4

For decades industries have been buying external services to supplement their own core competencies. The pharmaceutical industry has been quite conservative in this regard, starting late with that process, but after outsourcing the chemical synthesis for small molecules mainly in the late 90s, the biopharma industry has also been outsourcing cGMP Drug Substance manufacturing for the last 15 years. This has created a multibillion USD CDMO market, which continues to grow in almost double digits. The panel will discuss best practices around the make or buy decision and the subsequent selection process of the ideal CDMO that best meets their needs.

Participants

Moderator: Christoph Winterhalter - Senior VP, Business Development, AGC Biologics

Panelist: Lene Hylling Axelsson - Corporate VP for Strategic Sourcing, Novo Nordisk A/S

Panelist: Kasper Møller - General Manager, AGC Biologics Copenhagen

Panelist: Morten Munk - Global Technology Partner, NNE

Panelist: Johannes R. Roebbers - CEO, Cilatus BioPharma Consulting AG

BREAK AND BREATHE

16:05 - 16:25
Extra Activity

Upper Level, Room 17

Enhance your conference experience by using simple breathing techniques, movement and light stretches in order to charge your body and mind for better decision making and more energy throughout the day.

Open to all. No prerequisites required. Standing and seated positions only.

Gene therapy transformation in North Carolina: A case study

16:30 - 17:30
Additional Program

Room B5

The field of gene therapy continues to accelerate, with 317 gene therapy clinical trials underway as of the end of the second quarter of 2018. University researchers, emerging biotechs, and large pharmaceutical companies are all investing in North Carolina to develop and manufacture gene therapies to address indications ranging from rare disease to oncology to antimicrobials, and paving the way to bring these potentially life-changing therapeutics to market.

This session will address some of the challenges involved in delivering gene therapies to patients, including regulatory hurdles, new manufacturing techniques, availability of a skilled workforce, and production and delivery timing constraints. Discover how North Carolina uses partnerships to accelerate time to market for these transformational therapies.

Participants

Moderator: Laura Rowley - Director, Life Science Economic Development, NCBiotech

Panelist: Michael Dombeck - VP, Business Development, Precision Biosciences, Inc.

Panelist: Caitlin Hamill-Ward - Sr. Regulatory Affairs Director, IQVIA Stem Cell Center

Panelist: Liza Rivera - Global Marketing Director, FUJIFILM Diosynth Biotechnologies

Panelist: Andrew Stober - Vice President, Manufacturing, AveXis

BREAK AND BREATHE

16:35 - 16:55
Extra Activity

Upper Level, Room 17

Enhance your conference experience by using simple breathing techniques, movement and light stretches in order to charge your body and mind for better decision making and more energy throughout the day.

Open to all. No prerequisites required. Standing and seated positions only.

Exhibit Hall Hospitality Receptions

17:45 - 18:45
Networking

Hall E

SESSIONS

DAY 2 - 06/11/2018

BIO-Europe

November 5–7, 2018
Bella Center Copenhagen
Copenhagen, Denmark

Evening Networking Reception with Buffet-style Dinner

18:45 - 23:00

Networking

Venue address:

Lokomotivværkstedet| Otto Busses Vej 5A | Building
OBV037 | 2450 København SV

This 120-year-old Central Train Workshop with floor-to-ceiling windows and a roof structure made of wood and glass creates an atmosphere filled with natural light and impressive architecture. The rustic 9,000 m2 hall has access to a magnificent garden with pavilions and an antique ticket booth. The central workshop carried out extensive inspections of the many steam locomotives serving Copenhagen, sometimes taking eight months to inspect all the components.

Tuesday, November 6, 2018, 19:00–23:00

[View website](#)

Buses:

18:30–19:15 Shuttle buses depart from the conference center to the evening event.

21:00–23:00 Shuttle buses depart from the evening event to all conference hotels.

SCHEDULE

DAY 2 - 06/11/2018

BIO-Europe

November 5–7, 2018
Bella Center Copenhagen
Copenhagen, Denmark

TIME	ACADEMIC PRESENTATIONS	ADDITIONAL PROGRAM	CELL AND GENE	EXTRA ACTIVITY	MAIN AGENDA	NETWORKING	PANELS	PARTNERING	PLENARY	PRESENTATIONS	STARTUP SLAM	WORKSHOPS
06:00				06:30 - Rise and Run for children with cancer								
07:00					07:45 - Registration and Exhibition Open	07:45 - Continental Breakfast						
08:00								08:00 - One-to-one meetings				
09:00	09:00 - University of Copenhagen – Building value out of curiosity: How basic research leverages the biopharmaceutical industry	09:00 - EU research funding for SMEs	09:00 - Commercialization of cell and gene therapies							09:00 - Company Presentations		09:00 - Power up partneringONE: Essentials
10:00		10:45 - Spotlight on Denmark: The place to conduct clinical trials	10:00 - Cell & Gene Company Presentation Track									10:00 - Power up partneringONE: Experienced users

SCHEDULE

DAY 2 - 06/11/2018

BIO-Europe

November 5–7, 2018
Bella Center Copenhagen
Copenhagen, Denmark

TIME	ACADEMIC PRESENTATIONS	ADDITIONAL PROGRAM	CELL AND GENE	EXTRA ACTIVITY	MAIN AGENDA	NETWORKING	PANELS	PARTNERING	PLENARY	PRESENTATIONS	STARTUP SLAM	WORKSHOPS
11:00			11:30 - Partnering landscape in advanced therapies	11:05 - BREAK AND BREATHE 11:35 - BREAK AND BREATHE								
12:00						12:00 - Luncheon			12:30 - Keynote Plenary Discussion: A day in the life of experienced dealmakers			
13:00												
14:00		14:00 - Using new business models to forge stronger partnerships in today's biopharmaceutical industry					14:00 - Biotech company creation in the EU: The role of EU-based VCs			14:00 - Company Presentations		

SCHEDULE

DAY 2 - 06/11/2018

BIO-Europe

November 5–7, 2018
Bella Center Copenhagen
Copenhagen, Denmark

TIME	ACADEMIC PRESENTATIONS	ADDITIONAL PROGRAM	CELL AND GENE	EXTRA ACTIVITY	MAIN AGENDA	NETWORKING	PANELS	PARTNERING	PLENARY	PRESENTATIONS	STARTUP SLAM	WORKSHOPS
15:00		15:15 - Make or buy decision and how to select the ideal CDMO					15:15 - Formulation in the drug product development process				15:00 - Startup Slam Copenhagen	
16:00		16:30 - Gene therapy transformation in North Carolina: A case study		16:05 - BREAK AND BREATHE 16:35 - BREAK AND BREATHE								
17:00						17:45 - Exhibit Hall Hospitality Receptions						
18:00						18:45 - Evening Networking Reception with Buffet-style Dinner						

SESSIONS

DAY 3 - 07/11/2018

BIO-Europe

November 5–7, 2018
Bella Center Copenhagen
Copenhagen, Denmark

Registration and Exhibition Open

07:45 - 17:45
Main Agenda

Registration: Entrance

Exhibition: Hall E and Hall C

Continental Breakfast

07:45 - 10:30
Networking

Hall E

One-to-one meetings

08:00 - 17:00
Partnering

Hall C

08:00 – 17:00 Please note: One-to-one meetings will take place all day depending on your partneri

Power up partneringONE: Essentials

09:00 - 09:30
Workshops

Hall C, Room 393

This session is for delegates new to partnering. What you can expect out of partnering, and what others expect from you will form the basis of this workshop. Principles around timing, human nature, and partnering etiquette will be applied to the partneringONE process. Come away from the session with a clear understanding of what you can do to generate the best ROI from partnering, at this and future events.

This session is being offered multiple times during BIO-Europe. Each session is limited to 9 people. Please reserve your seat by adding the session to your personal agenda in your partnering account. Or drop by the Power Zone, by the partnering help desk, with any questions.

Participants

Speaker: Lisa Methley - Senior Director, Online Strategy, EBD Group

Company Presentations

09:00 - 12:00
Presentations

[2018 list of Presenting Companies](#)

Rooms B1, B2, B3

Is the ecosystem of translational metabolic research in greater Copenhagen sustaining a competitive biotech industry?

10:00 - 11:00
Metabolic Track

Room B4

Participants

Moderator: Tomas Landh - Innovation Sourcing VP, Senior Principal Scientist, Novo Nordisk

Panelist: Henrik Blou - CEO, Gubra ApS

Panelist: Brian Bloomquist - Diabetes External Innovation, Eli Lilly and Company

Panelist: Jørgen Drejer - CEO, Saniona

Panelist: Dorte X. Gram - CEO, Pila Pharma

Panelist: Adam Steensberg - Chief Medical and Development Officer, Executive VP Development, Zealand Pharma A/S

Power up partneringONE: Experienced users

10:00 - 10:30
Workshops

Hall C, Room 393

This session is for delegates familiar with partnering who want to up their game. Best practices for collaborating with colleagues, saving time, increasing response rates and acceptance rates will be discussed in terms of partneringONE, including new power features to support optimal partnering etiquette. Come away from the session with a clear understanding of how partneringONE can support your company to maximize ROI from partnering, at this and future events.

This session is being offered multiple times during BIO-Europe. Each session is limited to 9 people. Please reserve your seat by adding the session to your personal agenda in your partnering account. Or drop by the Power Zone, by the partnering help desk, with any questions.

Participants

Speaker: Lisa Methley - Senior Director, Online Strategy, EBD Group

Harmonization of Health Technology Assessment in Europe

10:30 - 12:00
Additional Program

Room B5

Health professionals, patients and institutions need to know whether or not a new medicine is an improvement. Health technology assessments (HTA) therefore seek to identify the added value of new medicines, comparing them with other products and existing therapies. In the European Union, HTAs are under the exclusive competence of the European member states. However, cooperation between member states in the field of HTA has existed for more than a decade. On January 31, 2018, the European Commission released a proposal to harmonize the clinical assessment of new drugs. And on October 3, 2018, the European Parliament adopted a new law that aims to boost cooperation between member states in the field of HTA. This panel will discuss the impact of a stronger collaboration on HTA within the EU. It will also provide hands-on information on how innovative biotech companies can benefit from the existing collaboration between the European HTA bodies and how a harmonized European HTA might impact drug development in the near future.

Participants

Moderator: Alexander Natz - Secretary General, European Confederation of Pharmaceutical Entrepreneurs, Belgium

Panelist: Daniel Reuter - Scientific Advisor, Methods Assessment and Prescribed Services Department, Federal Joint Committee (Healthcare), Germany

Panelist: Zoe Garrett - Senior Technical Adviser, EUnetHTA, National Institute for Health and Care Excellence, United Kingdom

Panelist: Bertram Häussler - Chairman, IGES Institute, Germany

Metabolic Pitch Showcase

11:00 - 12:45
Metabolic Track

Jan Alenfall – CEO, Follicum AB

Henrik Blou – CEO, Gubra ApS

Zachary Gerhart-Hines – Associate Professor, University of Copenhagen; Chief Scientific Officer, Embark Biotech ApS

H. Bjørn Nielsen – Chief Scientific Officer, Clinical Microbiomics

Alexander Hovard Sparre-Ulrich – CEO, Antag Therapeutics

SESSIONS

DAY 3 - 07/11/2018

BIO-Europe

November 5–7, 2018
Bella Center Copenhagen
Copenhagen, Denmark

BREAK AND BREATHE

11:05 - 11:25

Extra Activity

Upper Level, Room 17

Enhance your conference experience by using simple breathing techniques, movement and light stretches in order to charge your body and mind for better decision making and more energy throughout the day.

Open to all. No prerequisites required. Standing and seated positions only.

BREAK AND BREATHE

11:35 - 11:55

Extra Activity

Upper Level, Room 17

Enhance your conference experience by using simple breathing techniques, movement and light stretches in order to charge your body and mind for better decision making and more energy throughout the day.

Open to all. No prerequisites required. Standing and seated positions only.

Luncheon

12:00 - 14:00

Networking

Seated Luncheon Hall B

Grab & Go Lunch Hall E

Side Event/Site Tour: AGC Biologics Facility, Copenhagen

13:45 - 16:45

Additional Program

FACILITY TOUR - [CLICK HERE](#) TO SIGN UP FOR TOUR (DEADLINE: November 2 – limited to 70 participants)

AGC Biologics - Copenhagen Facility

Tour Schedule

12:45 pm – Bus pick up at BIO-Europe Bella Center – meeting spot to be communicated

13:30 pm – Welcome and introduction at AGC Biologics Copenhagen, Kasper Møller, Site Head

2:00 pm – Facility Tour

– Guided site tour in small subgroups through facility visiting labs and cGMP suites

– Light refreshments and discussion with our Executive Team and Subject Matter Experts

3:45 pm – Bus back to Bella Center (taxi to airport available if needed)

AGC Biologics is a leading global Contract Development and Manufacturing Organization with a strong commitment to deliver the highest standard of service to our clients. We have an extensive network of cGMP facilities in the US, Europe and Asia. We offer deep industry expertise, innovative solutions and customized services for the cGMP manufacture of protein-based therapeutics using mammalian and microbial production systems.

AGC Biologics' Copenhagen cGMP manufacturing facility operates both microbial and mammalian production lines at a variety of scales. Take the tour to see our facility first hand and understand our capabilities for manufacture of protein therapeutics using microbial and mammalian production systems.

Whatever the challenge, see for yourself why AGC Biologics is your best solution for clinical and commercial manufacturing.

www.agcbio.com

CLOSING RECEPTION: Thank you, Copenhagen – Hamburg Ahoy!

16:00 - 17:00

Networking

Reception to welcome BIO-Europe 2019, November 11-13 in Hamburg, Germany

Hall E, Booth #97

SCHEDULE

DAY 3 - 07/11/2018

BIO-Europe

November 5–7, 2018
Bella Center Copenhagen
Copenhagen, Denmark

TIME	ADDITIONAL PROGRAM	EXTRA ACTIVITY	MAIN AGENDA	METABOLIC TRACK	NETWORKING	PARTNERING	PRESENTATIONS	WORKSHOPS
07:00			07:45 - Registration and Exhibition Open		07:45 - Continental Breakfast			
08:00						08:00 - One-to-one meetings		
09:00							09:00 - Company Presentations	09:00 - Power up partneringONE: Essentials
10:00	10:30 - Harmonization of Health Technology Assessment in Europe			10:00 - Is the ecosystem of translational metabolic research in greater Copenhagen sustaining a competitive biotech industry?				10:00 - Power up partneringONE: Experienced users
11:00		11:05 - BREAK AND BREATHE 11:35 - BREAK AND BREATHE		11:00 - Metabolic Pitch Showcase				
12:00					12:00 - Luncheon			
13:00	13:45 - Side Event/ Site Tour: AGC Biologics Facility, Copenhagen							
14:00								
15:00								

SCHEDULE

DAY 3 - 07/11/2018

BIO-Europe

November 5-7, 2018
Bella Center Copenhagen
Copenhagen, Denmark

TIME	ADDITIONAL PROGRAM	EXTRA ACTIVITY	MAIN AGENDA	METABOLIC TRACK	NETWORKING	PARTNERING	PRESENTATIONS	WORKSHOPS
16:00					16:00 - CLOSING RECEPTION: Thank you, Copenhagen – Hamburg Ahoy!			